Geron, University of Edinburgh to develop stem-cell derived cell types

By Elaine Rigoli

Tampa, Fla., Aug. 7 - Geron Corp. and the University of Edinburgh have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs).

The cell types are hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, including osteoarthritis, bone fractures and osteoporosis.

The milestones and endpoints of these programs were collaboratively defined, with Geron contributing its expertise on the design and execution of Investigational New Drug enabling studies, officials said.

The company noted that the lead investigators include experienced hESC researchers and practicing physicians whose expertise will be useful to progress these cell types to the clinic.

The University of Edinburgh's Center for Regenerative Medicine is based at the Center for Biomedical Research and is located in Edinburgh, Scotland.

Geron is a Menlo Park, Calif.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.